Review access failures, update the clinical escalation workflow and correct compliance calendars before approving another supplier commitment. Our recommendation is to make this an evidence-cleanup week—not a search for the lowest advertised starting price.
What does the new CDC report say about treatment continuity?
November 12 publication; July–August 2025 survey data. CDC reports that 44% of surveyed GLP-1 users modified their medication use from the prescribed approach. Among those reporting modifications, 38% cited cost and 36% cited availability; 22.6% of GLP-1 users reported using a compounded version. These are weighted, self-reported national survey findings—not November 2026 clinic-performance benchmarks or proof that a particular supplier caused interruptions. (cdc.gov)
Buyer action: Separate failed fulfilment, affordability problems, clinical pauses and patient-requested changes in your exception queue. Ask clinicians to review medication-use changes; do not treat dose stretching as a procurement workaround.
Does the new FDA safety communication require a supplier switch?
Safety carry-forward — November 9. FDA is requiring GLP-1 receptor agonist labelling changes concerning a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION, a rare eye condition that can cause permanent vision loss. FDA directs healthcare professionals to counsel patients about relevant visual symptoms and arrange prompt evaluation when NAION is suspected. (fda.gov)
Buyer action: Assign the medical director—not procurement—to approve updated patient communications. Ask dispensing partners how safety updates reach counselling scripts, patient materials and urgent escalation teams. This communication does not establish that one dispensing partner is safer than another.
Is November 27, 2026 still the small-dispenser DSCSA deadline?
No—not for the specified requirements covered by FDA’s extended exemption. FDA’s current notice extends that exemption until November 27, 2027. Its small-dispenser definition uses the owning company’s total of 25 or fewer full-time licensed pharmacists or qualified pharmacy technicians as of November 27, 2026—not the clinic’s prescriber count. (fda.gov)
NABP’s November reminder stresses that the exemption does not suspend all obligations: suspect-product identification, quarantine and investigation remain important requirements. (pulse.pharmacy)
Buyer action: Where DSCSA applies, request a written applicability assessment, the basis for any claimed exemption and a demonstration of suspect-product handling. Do not accept “we are exempt” as the whole answer.
Which year-end price condition needs an immediate check?
Current programme snapshot—not a newly announced price cut. NovoCare’s provider page offers qualifying new patients two monthly fills of Wegovy injection at $199 each for the 0.25 mg and 0.5 mg strengths through December 31, 2026. It lists $349 for subsequent standard-dose injection fills and $399 for Wegovy HD 7.2 mg, subject to terms. (novocare.com)
Buyer action: Audit the patient affordability estimate shown at enrolment. Display the introductory period, the continuing-price assumption and a requirement to reconfirm January terms. Do not turn a dated promotion into a year-long patient promise.
Sources cited on this page
- cdc.gov · Source 1 ↗https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- pulse.pharmacy · Source 4 ↗https://pulse.pharmacy/resources/newsroom/closing-the-gaps-in-your-dscsa-compliance-program/
- novocare.com · Source 5 ↗https://www.novocare.com/hcp/delivery.html